Immunologic Timing and Therapeutic Sequencing of Locoregional Therapy and Immunotherapy in Hepatocellular Carcinoma
Journal of Visualized Experiments · 2026-11-03 · (237)
DOI: 10.3791/74529 ↗At a glance
Video/Audio in Journal of Visualized Experiments, published online on 2026-11-03. Written by Yu-Han Guo and 2 co-authors. Institution: Department of Radiotherapy, The First Hospital of Jilin University. Major MEDLINE topics: Liver Neoplasms, Carcinoma, Hepatocellular, Immunotherapy.
Abstract (original language)
Immune checkpoint inhibitor combinations have improved outcomes in hepatocellular carcinoma, but durable benefit remains uneven and the optimal integration of locoregional therapy is unresolved. Local interventions can release tumor antigens, alter vascular and stromal barriers, and recruit innate and adaptive immune cells. These effects can coexist with tissue repair, angiogenic signaling, myeloid recruitment, and renewed checkpoint expression. This narrative review examines therapeutic timing for clinicians and translational researchers. A targeted PubMed search, publisher reports, and reference checking informed the revision; studies were selected for relevance to human immune kinetics, clinical schedules, safety, and biomarker validation. This review compares thermal ablation, transarterial chemoembolization, yttrium-90 radioembolization, irreversible electroporation, and stereotactic body radiotherapy; evaluates checkpoint inhibition before, after, or overlapping local treatment; and assesses candidate scheduling biomarkers. Human studies document selected immune changes, while phase 3 trials show that some treatment combinations extend progression-free survival. However, these trials do not isolate timing, and observational schedule comparisons cannot establish a causal advantage or a universal interval. A modality- and patient-specific hypothesis is therefore discussed in which measured immune state and hepatic reserve could inform future scheduling trials. No biomarker-triggered schedule has demonstrated clinical utility. Serial tissue and blood sampling, pharmacokinetic assessment, and schedule-specific randomization are needed before an immunogenic window can guide routine care.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Radiotherapy, The First Hospital of Jilin University.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University; jiaoyan@jlu.edu.cn.
Cite
APA
Guo, Y. H., Yu, J., & Jiao, Y. (2026). Immunologic Timing and Therapeutic Sequencing of Locoregional Therapy and Immunotherapy in Hepatocellular Carcinoma. Journal of Visualized Experiments. https://doi.org/10.3791/74529
Vancouver
Guo YH, Yu J, Jiao Y. Immunologic Timing and Therapeutic Sequencing of Locoregional Therapy and Immunotherapy in Hepatocellular Carcinoma. Journal of Visualized Experiments. 2026. doi:10.3791/74529
BibTeX
@article{Guo2026,
author = {Guo, Yu-Han and Yu, Jian and Jiao, Yan},
title = {Immunologic Timing and Therapeutic Sequencing of Locoregional Therapy and Immunotherapy in Hepatocellular Carcinoma},
journal = {Journal of Visualized Experiments},
year = {2026},
number = {237},
doi = {10.3791/74529}
}
EUVIMED